Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026299 · ClinicalTrials.gov registry record · Phase 1
Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
A Phase 1 study of Colorectal Cancer, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 12
- Study locations
NCT00026299 is a Phase 1 study of Colorectal Cancer that has completed, run by University of Chicago. The registered enrollment target is 14 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (99% lower). The trial reports 12 study locations across 3 states.
The verdict
NCT00026299, a Phase 1 study of Colorectal Cancer, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 12
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of colorectal cancer. Combining chemotherapy with gefitinib may kill more tumor cells. PURPOSE: Phase I/II trial to compare the effectiveness of chemotherapy with or without gefitinib in treating patients who have metastatic or locally recurrent colorectal cancer.
Conditions Studied
Interventions
- DRUG oxaliplatin
- DRUG ZD1839
Study Locations (12)
Illinois
- University of Chicago Cancer Research Center - Chicago
- Louis A. Weiss Memorial Hospital - Chicago
- Decatur Memorial Hospital Cancer Care Institute - Decatur
- Evanston Northwestern Health Care - Evanston
- Ingalls Memorial Hospital - Harvey
- LaGrange Memorial Hospital - LaGrange
- Loyola University Medical Center - Maywood
- Oncology/Hematology Associates of Central Illinois, P.C. - Peoria
- Central Illinois Hematology Oncology Center - Springfield
Indiana
- Fort Wayne Medical Oncology and Hematology, Inc. - Fort Wayne
- Memorial Hospital of South Bend - South Bend
Michigan
- Oncology Care Associates, P.L.L.C. - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2001-09 |
| Est. Completion | 2005-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026299
The ClinicalTrials.gov registry entry for NCT00026299 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which oxaliplatin is the first listed.
NCT00026299 reports 12 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Indiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT00026299 about?
NCT00026299 is a clinical study titled "Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of colorectal cancer. Combining chemotherapy with gefitinib may kill mor...
What is the current status of trial NCT00026299?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2001-09. Estimated completion is 2005-02.
What conditions does trial NCT00026299 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT00026299?
The interventions under investigation include: oxaliplatin (DRUG), ZD1839 (DRUG).
Who is sponsoring clinical trial NCT00026299?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00026299 being conducted?
This trial has 12 study locations across Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.